Ken Griffin Monte Rosa Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$3.59 - $6.97 $81,493 - $158,219	22,700 Added 267.06%	31,200 $165,000
Q2 2024 Aug 14, 2024	BUY	$3.38 - $7.86 $24,674 - $57,378	7,300 Added 608.33%	8,500 $31,000
Q1 2024 May 15, 2024	SELL	$4.26 - $8.46 $41,748 - $82,908	-9,800 Reduced 89.09%	1,200 $8,000
Q4 2023 Feb 14, 2024	BUY	$2.5 - $5.93 $27,500 - $65,230	11,000 New	11,000 $62,000
Q4 2022 Feb 14, 2023	BUY	$6.71 - $9.72 $9,394 - $13,608	1,400 New	1,400 $10,000

43.9M

141K

31.2K

Ticker GLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,713,900
Market Cap $395M
Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.